Generic Celltrion Project
- Overview
-
The global generic market, which takes up two-thirds of the global pharmaceutical market, is expected to reach a total market worth of 833 billion dollars by 2021. In recognition of this potential for market growth, Celltrion created the Global Chemical Development Division to strengthen our position in the global pharmaceutical market.
- Business Strategy
-
Starting with Temixys, the first incrementally modified drug (IMD) for HIV to be approved by the United States FDA (2018), Celltrion is carrying out a strategy to take the lead in the global generic pharmaceutical market by entering the US and global tender markets, and building its global distribution network.
-
- Secure presence in
the global market -
- Develop IMDs and generic drugs
- Enter the US and global tender markets
- Perform initial clinical trials for new drugs
- Secure presence in
-
- Acquire new portfolios and
boost global sales -
- Carry out global clinical trials for new drugs
- Secure 20 or more generic products in portfolio
- Expand global distribution network
- Acquire new portfolios and
-
- Become a global
pharmaceutical company -
- Globally launch new drugs
- Build a stable sales structure
- Take the lead in the global generic pharmaceutical market
- Become a global
Business Competencies
-
- World-class knowledge in development,
clinical trial, and approval -
- World-class knowledge in development,
clinical trials, and approvals - Cooperation and synergy with affiliate, CelltrionPharm, specializing in generic pharmaceutical production
- World-class knowledge in development,
- World-class knowledge in development,
-
- Production and quality competencies
recognized by leading regulators -
- First Korean company with production facilities certified by US FDA and UK MHRA
- Capable of manufacturing five billion tablets per year
- Operates a stable SCM encompassing production and distribution
- Production and quality competencies
-
- R&D facilities specializing in
generic pharmaceutical products -
- Runs a research center dedicated to generic pharmaceutical products
- Continues to develop pipelines for IMDs, new chemical entities, and generic drugs
- Researches platform technologies including drug delivery systems
- Researches ways to improve production efficiency
- R&D facilities specializing in
